Key points are not available for this paper at this time.
Combination treatment with eprenetapopt and azacitidine is well-tolerated yielding high rates of clinical response and molecular remissions in patients with TP53-mutant MDS and oligoblastic AML.
Sallman et al. (Fri,) studied this question.